IgA nephropathy is a type of kidney disease that occurs when abnormal deposits of immunoglobulin A (IgA) build up in the kidneys. IgA is an antibody that helps the body fight off infection. When too much IgA accumulates in the kidneys, it can cause inflammation and damage the organ’s filtering system. This can lead to a decrease in kidney function and, in some cases, kidney failure. While there is currently no cure for IgA nephropathy, there are treatments available to manage the condition and slow its progression. In recent years, researchers have been exploring the possibilities of treating IgA nephropathy with innovative therapies.
IgA nephropathy is an autoimmune disorder in which the body produces an excess amount of IgA, an antibody that helps the body fight off infection. When too much IgA accumulates in the kidneys, it can cause inflammation and damage the organ’s filtering system. This can lead to a decrease in kidney function and, in some cases, kidney failure. IgA nephropathy is the most common type of glomerulonephritis, a group of diseases that affect the glomeruli, or tiny filters in the kidneys. It is estimated to affect up to 20 percent of people with chronic kidney disease.
The most common symptom of IgA nephropathy is proteinuria, or excessive amounts of protein in the urine. Other symptoms may include: • Swelling in the legs, feet, and hands • High blood pressure • Fatigue • Foamy or bubbly urine • Pain in the abdomen or sides • Blood in the urine • Decreased urine output
IgA nephropathy is typically diagnosed through a physical examination, lab tests, and imaging tests. A physical exam may reveal signs of swelling or high blood pressure. Lab tests may include a urine test to check for protein and blood in the urine, and a blood test to check levels of creatinine, a waste product that is usually filtered out of the blood by the kidneys. Imaging tests such as an ultrasound or CT scan may be used to look for signs of kidney damage.
The primary goal of treatment for IgA nephropathy is to reduce inflammation and slow the progression of the disease. Treatment may involve medications such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) to control high blood pressure and reduce proteinuria. Other medications, such as corticosteroids and immunosuppressants, may be used to reduce inflammation. In some cases, surgery may be necessary to remove damaged parts of the kidneys.
In recent years, researchers have been exploring the possibilities of treating IgA nephropathy with innovative therapies. One such therapy is stem cell therapy, which involves injecting healthy stem cells into the kidneys to replace damaged cells and reduce inflammation. This therapy has been found to be effective in slowing the progression of IgA nephropathy and improving kidney function. Another innovative therapy is extracorporeal photopheresis (ECP), which uses ultraviolet light to break down IgA deposits in the kidneys. This therapy has been found to be effective in reducing proteinuria and slowing the progression of the disease. Finally, gene therapy has been explored as a potential treatment for IgA nephropathy. In this therapy, healthy genes are injected into the kidneys to replace the mutated genes that cause the disease. While this therapy is still in its early stages, it has been found to be effective in reducing inflammation and slowing the progression of the disease.
IgA nephropathy is a type of kidney disease that occurs when abnormal deposits of immunoglobulin A (IgA) accumulate in the kidneys. While there is currently no cure for IgA nephropathy, there are treatments available to manage the condition and slow its progression. In recent years, researchers have been exploring the possibilities of treating IgA nephropathy with innovative therapies, such as stem cell therapy, extracorporeal photopheresis, and gene therapy. While these therapies are still in their early stages, they have been found to be effective
1.
Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.
2.
recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.
3.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
4.
Durvalumab Wins FDA Approval in Limited-Stage SCLC
5.
Telehealth in the pandemic era resulted in fewer therapy interruptions.
1.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
2.
CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights
3.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
4.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
5.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation